Search results
Results from the WOW.Com Content Network
The case originated in the Southern District of New York, where Sandoz sued to invalidate Teva's patent on a drug for the treatment of multiple sclerosis.In the Markman hearing, Sandoz argued that a claim was fatally indefinite for failing to identify which of three possible meanings a particular claim term, related to the molecular weight of a component of the drug, should be interpreted to have.
U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices - sometimes by more than 1,000% - and ...
(Reuters) -Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.
Inc., the Federal Circuit affirmed that the standard of review would be de novo. [16] De novo is defined as an appellate court reviewing a lower court's decision with without regard to the lower court's decision. [17] In a case concerning claim interpretation, the higher court will not consider the lower court's decision in interpreting a claim.
Teva Canada launched Novo-Sildenafil, a generic version of Viagra, on the day the Supreme Court of Canada released its decision. [ 5 ] [ 21 ] [ 22 ] On August 5, 2014, the Supreme Court of British Columbia certified a class action against Pfizer.
The pharmaceutical company Teva has reached a $4.25 billion nationwide settlement, potentially resolving thousands of lawsuits over its role in the U.S. opioid crisis. The money will go primarily ...
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Reuters reported that Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) CEO said the company will finalize the U.S. opioid settlement by the end of 2022 and start paying in 2023. CEO Kare Schultz ...